Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Longeveron Inc. - Class A Common stock (NQ:LGVN)

0.8287 -0.0013 (-0.16%)
Streaming Delayed Price Updated: 12:03 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Longeveron Inc. - Class A Common stock

< Previous 1 2 3 4 Next >
Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient
From Longeveron
Via GlobeNewswire
Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update
From Longeveron
Via GlobeNewswire
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Present ‘Important’ Lomecel-B(TM) Data at the 17th Clinical Trials on Alzheimer’s Disease Conference
Via Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) to Present at This Month’s Congenital Heart Surgeons’ Society Annual Meeting
Via Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) CEO to Participate in Fireside Cat at UBS Virtual Organ Restoration and Cell Therapy Day
Via Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) to Participate at the Cell & Gene Meeting on the Mesa
Via Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Announces Alignment with FDA on Development Pathway for Lomecel-B(TM) in HLHS
Via Investor Brand Network
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Announces Participation at H.C. Wainwright 26th Annual Global Investment Conference
Via Investor Brand Network
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Reports on Q2 2024 Financial Results, Business Highlights
Via Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Schedules Release of Q2 2024 Financial Results, Earnings Conference Call
Via Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Lomecel-B(TM) Study Results Presented at the Alzheimer’s Association International Conference
Via Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Closes on $9M Registered Direct Offering
Via Investor Brand Network
5 Stocks in the News to Watch Now: LGVN, PRSO, SIRI, INBS, VTAK
Via AB Newswire
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Expands Growing Telecommunications Sector Through New Subsidiary
Via Investor Brand Network
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Enters into $9M Registered Direct Offering
Via Investor Brand Network
InvestorNewsBreaks – Longeveron Inc.’s (NASDAQ: LGVN) Lomecel-B(TM) Granted Fast Track Designation for Treatment of Mild Alzheimer’s Disease
Via Investor Brand Network
TechMediaBreaks – Longeveron Inc.’s (NASDAQ: LGVN) Lomecel-B(TM) Granted RMAT Designation for the Treatment of Mild Alzheimer’s Disease
Via Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Elected New Board Member at Annual Stockholder Meeting
Via Investor Brand Network
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Announces Strategic Board Appointment of Gene Therapy Pioneer Roger Hajjar, MD
Via Investor Brand Network
InvestorNewsBreaks – Longeveron Inc.’s (NASDAQ: LGVN) Presentation at Virtual Life Sciences Investor Forum Made Available for Online Viewing
Via Investor Brand Network
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Life Sciences Virtual Investor Forum Agenda Announced for June 20th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Exercise Warrants for $4.4M, Present at Virtual Life Sciences Investor Forum
Via Investor Brand Network
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Announces CEO Participation in Emerging Growth Conference, Completion of Investigator Meeting for Phase 2b Clinical Trial
Via Investor Brand Network
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
From FN Media Group LLC
Via GlobeNewswire
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Participate in Upcoming Emerging Growth Virtual Conference
Via Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Launches New Business, Eyes Opportunity in Contract Manufacturing
Via Investor Brand Network
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Set to Participate in Upcoming BIO International Convention 2024
Via Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Releases Financial Report, Business Update for Q1 2024
Via Investor Brand Network
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.